Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02520128
Other study ID # UCL/13/0376
Secondary ID C2921/A17558
Status Completed
Phase N/A
First received
Last updated
Start date March 2016
Est. completion date June 30, 2020

Study information

Verified date December 2020
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

IMRiS is a phase II trial which aims to assess the feasibility, efficacy and toxicity of Intensity Modulated Radiotherapy (IMRT) in three different cohorts of patients with primary bone and soft tissue sarcoma and to demonstrate whether IMRT can improve on current clinical outcomes. Cohort 1 of the trial is now closed to recruitment.


Description:

IMRiS is a prospective multicentre phase II trial of Intensity Modulated Radiotherapy (IMRT). The trial is aiming to evaluate the role of intensity modulated radiotherapy (IMRT) in soft tissue and bone sarcomas. Three separate sarcoma cohorts will be studied and will be analysed separately. Patients will be enrolled in one of three cohorts depending on the type of sarcoma they have: Cohort 1- Patients with Limb/limb girdle soft tissue sarcoma receiving (neo)-adjuvant radiotherapy. (closed to recruitment) Cohort 2- Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy. Cohort 3- Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant radiotherapy. Dose schedules for each Cohort have been indicated in the Trial Arm description. Radiotherapy will be delivered with fixed beam IMRT, arc IMRT techniques, or tomotherapy. All trial patients will be followed up until death or a maximum of three years from the date of registration in the trial. The theoretical advantage to IMRT is the potential reduction in late toxicity and subsequent potential for functional improvement. There have been no prospective studies to date powered to address this, particularly where IMRT is used post-operatively. IMRiS cohort 1 will address this question and establish if the use of IMRT will reduce late normal tissue toxicity. In cohorts 2 & 3, the aim is to establish if the use of IMRT will enable the achievement of a radiotherapy treatment plan that delivers the optimal dose while keeping within normal tissue tolerances. There have been no clinical trials of IMRT in Ewing sarcoma and there is very little published on the use of IMRT in high grade bone sarcomas and chordomas. It is important to establish the feasibility of IMRT to achieve the required radiation doses to the tumour, and to prospectively document the side effects of treatment in this setting. IMRiS will address this in cohort 2 and cohort 3.


Recruitment information / eligibility

Status Completed
Enrollment 191
Est. completion date June 30, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. Histologically proven soft tissue sarcoma of the upper or lower limb or limb girdle (Cohort 1), OR, Ewing sarcoma of bone arising in the pelvis or spine (Cohort 2) , OR, High grade primary bone sarcoma (non-Ewing) or Chordoma arising in the pelvis/spine (Cohort 3) 2. Patients requiring (neo)adjuvant or definitive radical radiotherapy 3. WHO performance status 0-2 4. Patients aged 16 years or more 5. Patients fit enough to undergo radiotherapy treatment and willing to attend follow up visits as per protocol 6. Women of child-bearing potential must have a negative pregnancy test prior to trial entry. Female patients of child-bearing potential and male patients with partners of child-bearing potential must agree to use adequate contraception methods, which must be continued for 3 months after completion of treatment. 7. Capable of giving written informed consent Exclusion Criteria: 1. Previous radiotherapy to the same site 2. Patients receiving concurrent chemotherapy with radiotherapy (neo-adjuvant chemotherapy prior to radiotherapy is permitted. 3. Patient with bone sarcomas eligible for proton beam radiotherapy; N.B. if a patient is not to have PBRT for whatever reason, they may be considered for IMRiS. 4. Paediatric type alveolar or embryonal rhabdomyosarcomas 5. Pregnancy (Women of child-bearing potential must have a negative pregnancy test prior to trial entry. Female patients of child-bearing potential and male patients with partners of child-bearing potential must agree to use adequate contraception methods, which must be continued for 3 months after completion of treatment 6. Patients with concurrent or previous malignancy that could compromise assessment of the primary and secondary endpoints of the trial; these cases must be discussed with UCL CTC prior to the patient being approached.

Study Design


Intervention

Radiation:
Intensity modulated radiotherapy (IMRT)
Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.

Locations

Country Name City State
Ireland St Luke's Hospital Dublin
United Kingdom Clatterbridge Cancer Centre Bebington
United Kingdom Belfast City Hospital Belfast
United Kingdom Queen Elizabeth Hospital Birmingham
United Kingdom Bristol Haematology and Oncology Centre Bristol
United Kingdom Adenbrookes' Hospital Cambridge
United Kingdom Velindre Hospital Cardiff
United Kingdom Cheltenham Hospital Cheltenham
United Kingdom University Hospital Coventry Coventry
United Kingdom Royal Derby Hospital Derby
United Kingdom Western General Hospital Edinburgh
United Kingdom Royal Devon & Exeter Foundation Trust Exeter
United Kingdom Beatson West of Scotland Cancer Centre Glasgow
United Kingdom St James' Institute of Oncology Leeds
United Kingdom Leicester Royal Infirmary Leicester
United Kingdom University College London Hospitals London
United Kingdom The Christie Hospital Manchester
United Kingdom Northern Centre for Cancer Care Newcastle
United Kingdom Northampton General Hospital Northampton
United Kingdom Norfolk and Norwich University Hospital Norwich
United Kingdom Nottingham City Hospital Nottingham
United Kingdom Churchill Hospital Oxford
United Kingdom Derriford Hospital Plymouth
United Kingdom Royal Preston Hospital Preston
United Kingdom Weston Park Hospital Sheffield
United Kingdom Southampton General Hospital Southampton
United Kingdom The Royal Marsden NHS Foundation Trust Sutton
United Kingdom Singleton Hospital Swansea

Sponsors (3)

Lead Sponsor Collaborator
University College, London Cancer Research UK, NCRI Radiotherapy Trials QA (RTTQA) Group

Countries where clinical trial is conducted

Ireland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cohort 1 (limb soft tissue sarcomas): The rate of grade 2 or more late soft tissue fibrosis at 2 years following radiotherapy as assessed by RTOG late radiation morbidity criteria. Late toxicity assessment measured using RTOG late radiation morbidity criteria. From date of registration until 2 years after date of registration.
Primary Cohorts 2 (Ewing's sarcoma of the spine/pelvis): The proportion of patients in whom 90% of the planPTV receives 95% of the optimal prescription dose. Cohorts 2 (Ewing's sarcoma of the spine/pelvis): The proportion of patients in whom 90% of the planPTV receives 95% of the optimal prescription dose. Upon completion of IMRT treatment
Primary Cohort 3 (Non-Ewing's primary bone sarcomas of the spine/pelvis): The proportion of patients in whom 80% of the planPTV receives 95% of the optimal prescription dose. Cohort 3 (Non-Ewing's primary bone sarcomas of the spine/pelvis): The proportion of patients in whom 80% of the planPTV receives 95% of the optimal prescription dose. Upon completion of IMRT treatment
Secondary Acute RT toxicity - (For all cohorts) In all 3 cohorts, Acute RT toxicity measured using RTOG acute radiation morbidity criteria. From date of registration up to 90 days after date of registration
Secondary Late RT toxicity - (For all cohorts) In all 3 cohorts, late toxicities measured using the RTOG/EORTC Late Radiation Morbidity Scoring Criteria (skin, subcutaneous tissue fibrosis, bone, joint stiffness) and Stern's scale for oedema From Day 91 after date of registration up to 3 years after date of registration
Secondary Patient reported Quality of life (QOL) - (All cohorts) All cohorts, patient reported Quality of life measured using EORTC QLQ-C30 quality of life questionnaire Timepoints- Baseline, 1 year and 2 year post treatment
Secondary Patient reported limb function (Cohort 1 only) For patients in Cohort 1 only, patient reported limb function measured using TESS questionnaire At timepoints - Baseline, 1 year and 2 years post Treatment
Secondary Disease free survival (All Cohorts) Disease free survival will be calculated from the date of registration to date of documented disease progression, or death from any cause. Where progression is suspected and subsequently confirmed by scans, the date of documented suspected progression will be used. Patients alive and disease-free will be censored at the date last seen. The start date for analysis will be the date of registration. From date of registration to date of documented disease progression assessed up to 3 years from date of registration
Secondary Overall survival (All Cohorts) Overall survival time will be calculated from date of registration to the date of death from any cause or end of trial follow up From date of registration to date of death or date of last follow-up assessment (assessed up to 3 years from date of registration)
Secondary Time to local tumour recurrence (All Cohorts, for adjuvant RT) Time to local tumour recurrence evaluation from date of registration to first diagnosis of recurrence (histological or radiological). From date of registration to date of documented recurrence within the irradiated site (assessed up to 3 years from date of registration)
Secondary Time to local disease progression (Cohorts 2 and 3, for definitive radical RT) Time to local disease progression evaluation from date of registration to first diagnosis of progression. From date of registration to date of documented progression (assessed up to 3 years from date of registration)
Secondary Response by RECIST 1.1 (Cohorts 2 and 3, for definitive radical RT) Response measured according to RECIST v 1.1 (for definitive radical RT) From date of registration to date of documented progression (assessed up to 3 years from date of registration)
Secondary Wound complications within 120 days of surgery (Cohort 1 only) Rate and severity of wound complications assessed up to 120 days post surgery. This is a composite outcome measure assessed by a clinical examination of the wound. From date of definitive surgery until 120 days post surgery
Secondary For individual plans (cohort 2 & 3) Percentage volume of planPTV receiving 95% of the prescription dose (50.4Gy/54Gy for cohort 2 and 60Gy/70Gy for cohort 3) Upon completion of IMRT treatment.
Secondary For individual plans (cohort 2 & 3) Dose delivered to 95%, 80%, 70%, 60% and 50% volume of planPTV. Upon completion of IMRT treatment.
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04337177 - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Phase 1
Active, not recruiting NCT02945800 - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Phase 2
Recruiting NCT06156410 - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Phase 1
Recruiting NCT05968768 - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Phase 2
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT05093322 - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02856048 - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Phase 2/Phase 3
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Completed NCT04956198 - Drug Sensitivity and Mutation Profiling
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Recruiting NCT06068075 - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD N/A
Active, not recruiting NCT03709680 - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT05734066 - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Phase 1/Phase 2
Completed NCT02044120 - ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma Phase 1